The Need for More Education on Prescribing Opioids

When hearing the term “opioids” several ideas come to mind: addiction, abuse, under-treatment, overtreatment, severe pain, and suspicion are just a few. Opioids are undoubtedly an extremely successful route of treatment for severe pain and play a huge role in daily pain management cases. However, there is always a discussion of the risks associated with prescribing this medication.

There is often an air of distrust between physician and patient when a patient insists on opioid therapy. Unfortunately, pain cannot be measured, and there needs to be trust when prescribing this drug class. The prescriber will not know if the patient really needs the opioid for pain management or if they have developed a dependence on it. The physician is put in a position where they could under-treat the patient by refusing therapy because of the risk of abuse, or they could over-treat the patient by believing their plea for a medication they were addicted to.

There are several guidelines already in place regarding opioid prescribing, but still, much of it is up to the physician’s discretion. Right now, there is a big push for more prescriber education on the topic. For example, in 2012, the FDA encouraged a single shared Risk Evaluation and Mitigation Strategy (REMS) which required manufacturers of extended release or long acting opioids to fund accredited education on safe opioid prescribing. Currently, this program has not reached its goal number of prescribers. However, I believe with the advancement of this program, physicians will be able to make more educated and thorough decisions when it comes to prescribing opioids.

Managing pain is extremely complex, yet education on the topic is lacking. The ultimate goal would be to maintain a patient-centered approach and treat the patient in a manner in which they are comfortable and compliant with. Perhaps with more education on the topic, the physician and pharmacist can work together to make a confident decision in how to proceed with drug therapy, and hopefully avoid the mistakes that have been occurring concerning opioid therapy.

I personally see this as an opportunity for pharmacists to get more involved in the prescribing process, as they have a stronger background education on the topic. Do you think this could play a role in pharmacists eventually gaining prescribing rights?

 

Read the full article here.

Alford, Daniel P.  Opioid Prescribing for Chronic Pain — Achieving the Right Balance through Education. N Engl J Med. 2016;374:301-3

 

Safer Use of Medications through Risk Evaluation and Mitigation Strategies

REMs or risk evaluation and mitigation strategies are a baseline of communication between drug and patient. The term itself is relatively new, but pharmacists have been practicing medication education since the beginning of practice. REMs are other wise known as risk minimization action places, because they are proposed to do exactly that. The purpose of REMs is to educate the patient on the medication they are taking to increase therapeutic benefit.

The FDA determines which medications go in certain risk categories and have different guidelines on how to ‘do’ the REMs. Most of the approves REMs are a handout that educates the patient on the medication and usually has some FAQs. Other medications may require verbal counseling to ensure the patient knowledgable on the medication they are about to take. Other high risk medications have iPledge and counseling with the pharmacist.

The goal of REMs is to minimize the risk to our patients and increase their therapeutic outcome through the use of different education strategies. Since pharmacists are at the center of patient and prescriber and patient and drug, it is our responsibility to ensure we are conducting necessary REMs. I believe that pharmacists will continue to play a bigger role in medication safety because of REMs, and that we have the ability to do so. As future pharmacist we need to be sure to give our patients all the information needed and answer any questions about medications to increase our patient’s therapeutic benefit. At my pharmacy, I always have information sheets printing out after the labels. I will be sure to always pass them along to be given to the patient.

 

Hennessy K., Williams K., Bongero D.
J Am Pharm Assoc (2003) 2010;50:556-562. doi:10.1331/JAPhA.2010.10532

Link to Article